Global Blood Therapeutics
171 Oyster Point Blvd., Suite 300
South San Francisco
Tel: (650) 741-7700
About Global Blood Therapeutics
Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders with significant unmet need. GBT’s lead product candidate is voxelotor (formerly known as GBT440), an oral, once-daily therapy that modulates hemoglobin’s affinity for oxygen, which the company believes inhibits hemoglobin polymerization in sickle cell disease.
115 articles with Global Blood Therapeutics
GBT and Advocates Launch Disease Awareness Campaign Focused on Breaking Down Stigmas Associated with Sickle Cell Disease
Company Also Launches Disease Awareness Campaign to Raise Awareness Among Physicians About the Silent Damage Caused by Sickle Cell Disease
Global Blood Therapeutics, Inc. announced that on July 1, 2019, the compensation committee of GBT’s board of directors granted 13 new employees options to purchase an aggregate of 4,000 shares of the company’s common stock with a per share exercise price of $53.93 and restricted stock units for an aggregate of 31,700 shares of the company’s common stock.
According to a BioSpace poll, over half (56%) of respondents are not happy with their current life sciences position. Are you one of the 56%? You deserve to be happy! Start working towards your happiness and check out job opportunities at these top companies!
Global Blood Therapeutics, Inc. announced the pricing of its underwritten public offering of 3,375,527 shares of its common stock for gross proceeds of approximately $200.0 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by GBT.
Global Blood Therapeutics Announces Proposed Public Offering of $200.0 Million in Shares of its Common Stock
Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.
6/17/2019Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
GBT Announces Updated 24-Week Efficacy Data from All Patients Enrolled in Phase 3 HOPE Study Showing Statistically Significant and Sustained Improvements in Hemoglobin with Voxelotor
Data Supporting the Potential of Voxelotor as a Disease-Modifying Treatment for Sickle Cell Disease (SCD) Published in The New England Journal of Medicineandto bePresented During Presidential Symposium at the 24thEuropean Hematology Association (EHA) Congress
The HOPE trial involved 274 patients with SCD from 60 institutions across 12 countries.
GBT Awards More than $200,000 in Grants to Five Nonprofit Organizations through New ACCEL Program Aimed at Improving Access to Healthcare for People Living with Sickle Cell Disease
Company Created ACCEL (Access to Excellent Care for Sickle Cell Patients Pilot Program) to Accelerate Development of Innovative Healthcare Programs for Sickle Cell Community
Global Blood Therapeutics, Inc. announced that on June 1, 2019, the compensation committee of GBT’s board of directors granted 19 new employees options to purchase an aggregate of 35,600 shares of the company’s common stock with a per share exercise price of $60.78 and restricted stock units for an aggregate of 96,700 shares of the company’s common stock.
GBT Announces Upcoming Data Presentations at 24th European Hematology Association (EHA) Congress Supporting Voxelotor Sickle Cell Disease Program
Phase 3 HOPE Study 24-Week Efficacy Results from Full Patient Cohort to be Presented During Presidential Symposium
Global Blood Therapeutics today reported recent business progress and financial results for the first quarter ended March 31, 2019.
All of the above-described awards were made under the GBT’s Amended and Restated 2017 Inducement Equity Plan (the Plan).
According to a recent BioSpace survey, 93% of respondents are open to a new job for the right opportunity. Are you one of the 93%? If so, keep your eyes open for those opportunities and don't stop looking. You never know what may come your way!
H.C. Wainwright Global Life Sciences Conference in London on Tuesday, April 9, 2019, at 10:10 a.m. British Summer Time.
Cowen and Company 39th Annual Health Care Conference in Boston on Monday, March 11, 2019, at 4:50 p.m. Eastern Time.
According to a recent BioSpace survey, 70% of life science employers indicated their company anticipates an increase in the number of open positions during 2019. So if you are on the job hunt, keep your eye out for new positions posted throughout the year!
Pre-NDA Meeting Completed and Company Announces FDA Agreed to a Rolling Submission of New Drug Application for Voxelotor for the Potential Treatment of Sickle Cell Disease
8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019, at 1 p.m. Eastern Time.
The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease